BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, June 4, 2025
Home » Topics » Conferences » American Association for the Study of Liver Diseases

American Association for the Study of Liver Diseases
American Association for the Study of Liver Diseases RSS Feed RSS

Hepatitis B virus rendering

Ausperbio bags $73M series B for hep B-targeting RNA therapy

Dec. 31, 2024
By Marian (YoonJee) Chu
Ausperbio Therapeutics Inc. raised $110 million from two financing rounds in 2024 to advance its lead antisense oligonucleotide candidate as a functional cure for chronic hepatitis B.
Read More
Hepatitis B virus rendering

Ausperbio bags $73M series B for hep B-targeting RNA therapy

Dec. 30, 2024
By Marian (YoonJee) Chu
Ausperbio Therapeutics Inc. raised $110 million from two financing rounds in 2024 to advance its lead antisense oligonucleotide candidate as a functional cure for chronic hepatitis B.
Read More
Liver and DNA
Endocrine/metabolic

New siRNA therapy candidate, ETX-312, shows efficacy in MASH mouse model

Dec. 5, 2024
Researchers from E-Therapeutics plc presented preclinical data for ETX-312, a GalNAc-conjugated short interfering RNA (siRNA), produced using the Galomic platform and being developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Read More
Hepatitis B virus
Infection

SA-1211, a dual-target siRNA with promising antiviral activity in AAV-HBV mice

Dec. 4, 2024
Researchers from Suzhou Siran Biotech Co. Ltd. presented the discovery and preclinical characterization of SA-1211, an N-acetylgalactosamine (GalNAc)-conjugated siRNA dimer targeting both hepatitis B virus (HBV) and PD-L1 gene expression, being developed as a potential new therapeutic candidate for the treatment of chronic hepatitis B (CHB).
Read More
Infection

Preclinical characterization of Tune-401, a first-in-class LNP-encapsulated epigenetic silencer therapy for hepatitis B

Dec. 4, 2024
Tune Therapeutics Inc. is evaluating Tune-401.
Read More
Gastrointestinal

EA-3571, a dual inhibitor of enteropeptidase and trypsin with efficacy in mouse model of MASH

Dec. 3, 2024
Recently presented preclinical data show that EA Pharma Co. Ltd.'s EA-3571 is a highly potent dual inhibitor of enteropeptidase and trypsin with luminal action, resulting in potential anti-insulin resistance and fat-burning properties.
Read More
Gastrointestinal

SRT-015 prevents acute liver injury in preclinical tests

Dec. 3, 2024
Genfit SA and its collaborators have described the preclinical efficacy of SRT-015, a liver-selective ASK1 inhibitor in models of liver failure.
Read More
Transmission electron micrograph of hepatitis B virus particles
Infection

Therapeutic hepatitis B vaccine generates robust HBc-specific T-cell responses in preclinical tests

Dec. 2, 2024
Researchers from presented preclinical data for AVX-70371, a novel therapeutic vaccine being developed for the treatment of chronic hepatitis B virus (HBV) infection.
Read More
Gastrointestinal

EA-3571, a dual inhibitor of enteropeptidase and trypsin with efficacy in mouse model of MASH

Dec. 2, 2024
Recently presented preclinical data show that EA Pharma Co. Ltd.'s EA-3571 is a highly potent dual inhibitor of enteropeptidase and trypsin with luminal action, resulting in potential anti-insulin resistance and fat-burning properties.
Read More
A microscopic image of liver tissue affected by metabolic dysfunction-associated steatotic liver disease.
Gastrointestinal

Orsobio ACMSD inhibitor reverses liver injury in preclinical models

Nov. 29, 2024
The enzyme aminocarboxymuconate semialdehyde decarboxylase (ACMSD) is a regulator of de novo NAD+ synthesis and is reduced in patients with advanced liver disease.
Read More
Previous 1 2 3 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 4, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 3, 2025.
  • Handshake with DNA, molecules

    Regeneron boosts obesity pipeline with Hansoh’s GLP-1/GIP for $2B

    BioWorld
    Regeneron Pharmaceuticals Inc. is adding to its obesity pipeline by in-licensing Hansoh Biomedical Co. Ltd.’s phase III dual glucagon-like peptide 1...
  • 3D illustration of pancreatic cancer

    ASCO 2025: Verastem has positive cancer data but stock sags

    BioWorld
    New dose-escalation data from Verastem Oncology’s phase I/II cancer study in China prompted the company to say it was encouraged by the efficacy results. However,...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing